Mosunetuzumab in Patients with CAR T Refractory non-Hodgkin Lymphoma
DECEMBER 07, 2019
Stephen Schuster, MD
Mosunetuzumab, an experimental immunotherapy, helped 22% of patients with B-cell non-Hodgkin lymphoma—whose lymphoma had progressed after CAR-T therapy—to achieve complete remission.
“There is still a large need for new treatments in relapsed or refractory cases, since some patients fail CAR-T and others are too sick to wait for cell manufacturing,” said Stephen J. Schuster, MD, director of the Lymphoma Program at the Abramson Cancer Center of the University of Pennsylvania. “One of the benefits of this treatment is that it’s ‘off-the-shelf,’ meaning it does not need to be manufactured for each patient.”
The open-label, multicenter phase 1/1b study trial examining mosunetuzumab—a full-length, fully humanized immunoglobulin G1 bispecific antibody targeting both CD3 and CD20—involved 270 patients and was presented at the American Society of Hematology (ASH) 2019 Annual Meeting in Orlando. Patients in Group B of the study, which was the portion presented at ASH 2019, received mosunetuzumab with step-up dosing on days 1, 8 and 15 of Cycle 1 and, subsequently, as a fixed-dose on day 1 of each 21-day cycle. Investigators noticed the maximum number of cycles was 17.
Of the 270 included, 85 patients had indolent non-Hodgkin lymphoma and of them, 82 were follicular lymphoma, 180 had aggressive non-Hodgkin lymphoma and 117 were diffuse large B-cell lymphoma or transformed follicular lymphoma. The primary outcome measure of the study was best objective response rate as measured by revised International Working Group criteria, maximum tolerated dose, and tolerability.
Among efficacy-evaluable patients across all dose levels, investigators observed objective response rates and complete remission in 62.7% and 43.3% of patients with indolent non-Hodgkin lymphoma, and 37.1% and 19.4% in patients with aggressive non-Hodgkin lymphoma. In regard to complete remissions, investigators noted most patients with either condition remained in remission.
Adverse events leading to discontinuation of treatment occurred in a small proportion of participants. Cytokine release syndrome occurred in 28.9% of patients, and most of these instances were classified as Grade 1 (20.0%) or Grade 2 (7.8%). Neurological adverse events were reported in 43.7% of patients, and common neurological adverse events included headaches (15.6%), insomnia (9.3%), and dizziness (9.3%).
Investigators pointed out there were no observed correlations between frequencies of cytokine release syndrome and neurological adverse events with mosunetuzumab exposure.
Based on the results of the trial, investigators suggested mosunetuzumab had favorable tolerability and durable efficacy profile in patients with pre-treated resistant or refractory B-cell non-Hodgkin lymphoma.
This study, titled “Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines,” was presented at ASH 2019.
Brought to you by: